Dr. John Cush RheumNow
4 years 8 months ago
Why Are Physicians Silent About Outrageous Drug Prices?
https://t.co/hLrUFCiKwm https://t.co/ZgRoW9Duo6
Dr. John Cush RheumNow
4 years 8 months ago
Hold Myophenolate or Not with COVID-19 Vaccination?
https://t.co/9Bp8huqJ6M https://t.co/AD11BmoZE8
Dr. John Cush RheumNow
4 years 8 months ago
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients
 https://t.co/MrywKZKcIV https://t.co/QgajVPdesg
Dr. John Cush RheumNow
4 years 8 months ago
Study 126 rheumatic disease (RMD) patients showed that post-vaccination flares of RMD are rare. Despite being on DMARDs, biologics, immunosuppressives, the rate of RMD reactivation was 0.007 person/mo. 5 mild articular flares in 3 women https://t.co/OWXWTedw3Q
Dr. John Cush RheumNow
4 years 8 months ago
Can PPI accelerate knee OA? UK cohort compared need for TKR in adults over 50yrs on PPI or H2 blockers. Those on omeprazole and pantoprazole had 21%-3& more TKR than H2B (but not elevated with lansoprazole, rabeprazole (HR=0.97) https://t.co/5TqFV3TpjG
This article was written by Dr. Milton Packer, who wonders why physicians are struggling to get their priorities straight.
Dr. John Cush RheumNow
4 years 8 months ago
FDA has approved an NGF inhibitor for arthritis in cats...yes CATS! Presumeably for OA, Solensia (frunevetmab) is a cat-specific MAb that binds nerve growth factor (NGF). In humans several NGF MAbs have failed (tanezumab in 2021) https://t.co/WcvXP8Bv21
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.
Dr. John Cush RheumNow
4 years 8 months ago
KEEPSaKe-1 Trial in PsA - IL-23 Inhibition is Effective
The KEEPSaKE-1 study in PsA has been published and shows that RIZ showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.
https://t.co/thYavd4dAR https://t.co/HnVtsrUgVB
While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.
Dr. John Cush RheumNow
4 years 8 months ago
JAMA cohort study of 5.9 million VA pts and with & without gout ( 556 521)-gout pts had higher rates of lower extremity amputation (HR 1.59), than those without gout. This was assoc w/ poor uric acid control (>7), but not urate lowering therapy. https://t.co/KiM3IBCCp4
Dr. John Cush RheumNow
4 years 8 months ago
Global Burden of Disease Study shows that globally, from 1990 to 2019, the age-standardized incidence rate (ASIR) of hip osteoarthritis increased from 17.02 per 100,000 persons to 18.70 per 100,000 persons https://t.co/OJOnkAw1Dy
Dr. John Cush RheumNow
4 years 8 months ago
JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/6dRd6gnkjc
